The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

Mounjaro and Zepbound. Those drugs brought in a combined $4.4 billion in sales for Lilly in this year’s third quarter. The drugmaker plans to start construction of the expansion next year.

Walking pneumonia, a lung infection caused by the bacterium Mycoplasma pneumoniae, tends to be most common among older children and adolescents but in 2024 has been rampant among young children ...